Posted by Michael Wonder on 08 Mar 2023
FDA accepts BioMarin's supplemental new drug application to expand use of Voxzogo (vosoritide) for injection to treat children with achondroplasia under the age of 5
7 March 2023 - FDA set PDUFA target action date of 21 October 2023.
BioMarin Pharmaceutical announced today that the US FDA has accepted the company's supplemental new drug application for Voxzogo (vosoritide) for injection to expand treatment in the US to include children with achondroplasia under the age of 5.
